{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:38:00Z","timestamp":1786736280543,"version":"build-2736575974"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Ophthalmol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/ijo.ijo_1161_19","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T23:13:33Z","timestamp":1574723613000},"page":"2075","source":"Crossref","is-referenced-by-count":15,"title":["Case report: Bilateral uveitis and  papillitis secondary to treatment with pembrolizumab"],"prefix":"10.4103","volume":"67","author":[{"given":"Carmen","family":"Navarro-Perea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garcia-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Perez-Blazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0301-4738.271350-1","first-page":"183","article-title":"A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma","author":"Kirollos","year":"2016","journal-title":"Pharmacotherapy"},{"key":"key-10.4103\/0301-4738.271350-2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0301-4738.271350-3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2146\/ajhp140768","article-title":"Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma","author":"Ivashko","year":"2016","journal-title":"Am J Health-Syst Pharm"},{"key":"key-10.4103\/0301-4738.271350-4","first-page":"46","article-title":"A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab","author":"Abu","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"key-10.4103\/0301-4738.271350-5","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/ICB.0000000000000368","article-title":"Pembrolizumab administration associated with posterior uveitis","author":"Aaberg","year":"2017","journal-title":"Retin Cases Brief Rep"},{"key":"key-10.4103\/0301-4738.271350-6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/ITT.S141577","article-title":"Safety of checkpoint inhibitors for cancer treatment: Strategies for patient monitoring and management of immune-mediated adverse events","author":"Davies","year":"2017","journal-title":"Immunotargets Ther"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:39:52Z","timestamp":1786732792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_1161_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":6,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"alternative-id":["271350"],"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1161_19","relation":{},"ISSN":["0301-4738"],"issn-type":[{"value":"0301-4738","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}